Results 211 to 220 of about 321,714 (246)

Synthesis of 5-Fluorouracil (5-FU) coated platinum nanoparticles and apoptotic effects on U87 human glioblastoma cells. [PDF]

Cancer Cell Int
Abed A, Karimi M, Nejati M, Hamblin MR, Mirzaei SA, Sarvizadeh M, Mirzaei H.   +6 more
europepmc   +1 more source

PRMT1-catalyzed NUSAP1 methylation enhances Notch2 signaling and 5-FU resistance in gastric cancer. [PDF]

Cell Death Dis
Jiang S, Li G, Peng S, Chen S, Pang Y, Cui H, Wang F.   +6 more
europepmc   +1 more source

Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201. [PDF]

Oncologist
Kam AE, Zhao F, Meropol NJ, Giantonio BJ, Diasio RB, Flynn PJ, Catalano P, Hartner L, Rowland KM, Song W, Mulcahy MF, Sinicrope FA, Whitehead RP, Mayer RJ, Petrelli N, O'Dwyer PJ, Hamilton SR, Cella D, Benson AB.   +18 more
europepmc   +1 more source

Metformin reverses 5-FU resistance induced by radiotherapy through mediating folate metabolism in colorectal cancer. [PDF]

Mol Med
Wang S, Lin Y, Zhao Q, Chen H, Du S, Zeng Z.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Formulation and characterization of Paclitaxel, 5-FU and Paclitaxel + 5-FU microspheres

International Journal of Pharmaceutics, 2004
The purpose of this study was to compare the combination (Paclitaxel + 5-FU microspheres) with a single drug chemotherapy (Paclitaxel and 5-FU microspheres) against metastatic breast cancer cell line (MDA-MB 435 S). The physicochemical characteristics of the microspheres (i.e.
Anshul, Gupte, Kadriye, Ciftci
openaire   +2 more sources

Effects of 5-FU

2010
5-fluorouracil (5-FU) is a chemotherapeutical agent used to treat cancers including breast and colorectal. Working as an antimetabolite to prevent cell proliferation, it primarily inhibits the enzyme thymidylate synthase blocking the thymidine formation required for DNA synthesis.
Peter M, Wigmore, Sarah, Mustafa, Maha, El-Beltagy, Laura, Lyons, Jariya, Umka, Geoff, Bennett   +5 more
openaire   +2 more sources

Conversion of a Nŏvel 5-Fluorouracil (5-FU) Derivative to 5-FU in Rats

Journal of Urology, 1983
The converting efficiency of a novel 5-FU derivative, 1, 3-didecanoyl-2-[6-[(5-fluorouracil-l-yl) carbonylamino] hexanoyl]glyceride (DFUG), to 5-FU was investigated in rat plasma. The degradation half-life of DFUG was 4.04 min when DFUG was incubated in rat plasma at 37 degrees C, though DFUG was considerably stable in buffers having different pH ...
K, Takada, H, Yoshikawa, S, Muranishi
openaire   +2 more sources

Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyloxymethyl-5-FU prodrugs

Journal of Pharmaceutical Sciences, 2003
The 3-alkylcarbonyloxymethyl-5-fluorouracil (3-ACOM-5-FU) prodrugs have been characterized by their solubilities in isopropyl myristate (S(IPM)) and partition coefficients between IPM and pH 4.0 buffer (K(IPM:AQ)). Estimated S(AQ) values have been obtained from S(AQ) = S(IPM)/K(IPM:AQ.) The abilities of the prodrugs to deliver total 5-FU species from ...
William J, Roberts, Kenneth B, Sloan
openaire   +2 more sources

Cyclophosphamide plus 5-FU versus 5-FU Alone in Advanced Gastric Carcinoma

Oncology, 2009
30 patients with advanced metastatic gastric adenocarcinoma, having a measurable indicator lesion, were randomized (1:2) to receive (intravenously) either weekly 5-fluorouracil alone (15 mg/kg) or combination treatment with cyclophosphamide (20 mg/kg) given on day 1 and 5-FU (15 mg/kg) given weekly on weeks 2–5, beginning on day 8.
R T, Chlebowski, J M, Weiner, I, Silverberg, A, Glass, J R, Bateman   +4 more
openaire   +2 more sources